Supplementary material to article by M. S. Vandikas et al. "Impact of Etanercept on Vitamin D Status and Vitamin D-binding Protein in Bionaïve Patients with Psoriasis"

Table SI. Inclusion and exclusion criteria for the patients with psoriasis and the healthy controls, respectively

Inclusion criteria

- Patients with psoriasis
- Caucasian Age ≥18 years
- Moderate-to-severe plaque psoriasis, defined as: Psoriasis Area Severity Index (PASI) ≥10 and/or Dermatology Life Quality Index (DLQI) ≥10.
- · Moderate-to-severe plaque psoriasis where other systemic treatments were ineffective or considered inappropriate.
- No previous tumour necrosis factor alpha (TNF-a) inhibitor exposure.
- Healthy controls Age ≥18 years.
- No history of psoriasis.
- No other inflammatory disorder of the skin, joints and/or bowel.
- Sex, age, and season matched to the patients with psoriasis.
- Exclusion criteria, for both patients and controls
- Pregnancy/lactation or plans for pregnancy.
- Ongoing other severe chronic or systemic disease, e.g. liver, kidney, cancer, or infectious disease.
- Treatment with oral steroids or other immunosuppressive/anti-inflammatory drugs and antibiotic treatment.
- Ongoing sunbed use or sunbed use during the past 4 weeks.
- Sun holiday during the past 4 weeks (sun holiday was defined as journey to a location where the ultraviolet (UV) index was ≥3 during the period of the journey).
- Use of vitamin D interactive medicine (e.g. anticonvulsants).
- Vitamin D substitution and/or the use of topical vitamin D analogues were not allowed during the study.

ActaDV